One connector, four scholarly indexes, real DOIs and legal free PDFs. Works in Claude and ChatGPT.
Paste it into Claude or ChatGPT as a custom connector. 3-day free trial.
Natalie Gukasyan, Alan K. Davis, Frederick Streeter Barrett, Mary P Cosimano, Nathan D. Sepeda, Matthew W. Johnson, Roland R. Griffiths
BACKGROUND: Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known about long-term outcomes. AIMS: This study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MDD who received psilocybin. METHODS: This randomized, waiting-list controlled study enrolled 27 patients aged 21-75 with moderate to severe unipolar depression (GRID-Hamilton Depression Rating Scale (GRID-HAMD) ⩾ 17). Participants were randomized to an immediate or delayed (8 weeks) treatment condition in which they received two doses of psilocybin with supportive psychotherapy. Twenty-four participants completed both psilocybin sessions and were followed through 12 months following their second dose. RESULTS: = 2.3, 2.0, 2.6, and 2.4, respectively). Treatment response (⩾50% reduction in GRID-HAMD score from baseline) and remission were 75% and 58%, respectively, at 12 months. There were no serious adverse events judged to be related to psilocybin in the long-term follow-up period, and no participants reported psilocybin use outside of the context of the study. Participant ratings of personal meaning, spiritual experience, and mystical experience after sessions predicted increased well-being at 12 months, but did not predict improvement in depression. CONCLUSIONS: These findings demonstrate that the substantial antidepressant effects of psilocybin-assisted therapy may be durable at least through 12 months following acute intervention in some patients.
Formatted from the source metadata, not typed by hand. For a whole reference list, use the citation generator or ask your assistant through Find Research.
Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151–158. https://doi.org/10.1177/02698811211073759
Gukasyan, Natalie, et al. "Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up." Journal of Psychopharmacology, vol. 36, no. 2, 2022, pp. 151–158, https://doi.org/10.1177/02698811211073759.
Gukasyan, Natalie, Alan K. Davis, Frederick Streeter Barrett, Mary P Cosimano, Nathan D. Sepeda, Matthew W. Johnson, and Roland R. Griffiths. "Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up." Journal of Psychopharmacology 36, no. 2 (2022): 151–158. https://doi.org/10.1177/02698811211073759.
Gukasyan N., Davis A. K., Barrett F. S. [и др.] Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up // Journal of Psychopharmacology. — 2022. — Vol. 36, № 2. — P. 151–158. — URL: https://doi.org/10.1177/02698811211073759
@article{gukasyan2022efficacy,
title = {{Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up}},
author = {Natalie Gukasyan and Alan K. Davis and Frederick Streeter Barrett and Mary P Cosimano and Nathan D. Sepeda and Matthew W. Johnson and Roland R. Griffiths},
journal = {Journal of Psychopharmacology},
year = {2022},
volume = {36},
number = {2},
pages = {151--158},
doi = {10.1177/02698811211073759},
url = {https://doi.org/10.1177/02698811211073759}
}TY - JOUR AU - Gukasyan, Natalie AU - Davis, Alan K. AU - Barrett, Frederick Streeter AU - Cosimano, Mary P AU - Sepeda, Nathan D. AU - Johnson, Matthew W. AU - Griffiths, Roland R. TI - Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up JO - Journal of Psychopharmacology VL - 36 IS - 2 SP - 151 EP - 158 PY - 2022 DA - 2022/02/01 DO - 10.1177/02698811211073759 UR - https://doi.org/10.1177/02698811211073759 ER -
Add Find Research to Claude or ChatGPT and ask in plain language. The assistant reads this record, finds the papers around it and cites only what it actually found:
Setup takes about a minute: add the connector, then start the free trial.
Record from OpenAlex; open-access location from Unpaywall and the indexes. Find Research links only to legal copies.